ABT vs DXCM
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data.
Side-by-side fundamentals
| Metric | ABT | DXCM | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $98.49 | $84.41 | |
| Market cap | $171.6B | $31.9B | |
| P/E as of 2026-10-08 | 31.70 | 33.60 | ABT lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.92 | |
| Net margin FY2025, SEC XBRL | +14.7% | +17.9% | DXCM higher |
| Gross margin FY2025, SEC XBRL | n/a | +60.1% | |
| Operating margin FY2025, SEC XBRL | +18.2% | +19.6% | DXCM higher |
| ROE FY2025, SEC XBRL | +12.4% | +30.5% | DXCM higher |
| ROA FY2025, SEC XBRL | +7.5% | +13.2% | DXCM higher |
| Debt / equity as of 2026-09-03 | 0.64 | 0.49 | DXCM lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.1% | +15.5% | DXCM higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +17.0% | DXCM higher |
| Dividend yield as of 2026-09-03 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | ABT higher |
| Beta as of 2026-09-03 | 0.18 | 0.89 | |
| 1-year return as of 2026-10-08 close | -26.6% | +24.5% | DXCM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.